Anti-Siglec-15 antibody and its application in drug preparation

By developing an anti-Siglec-15 antibody that binds to Siglec-15 with high affinity, reversing its immunosuppressive effect, the problem of immune escape in the tumor microenvironment was solved, enhancing the efficacy of immunotherapy, especially significantly inhibiting tumor growth in PD-1/PD-L1 non-responsive patients.

CN114437216BActive Publication Date: 2026-11-17SHANGHAI JMT BIO TECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202111302076.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-09-17
Filing Date
2021-11-04
Publication Date
2026-11-17
Estimated Expiration
2041-11-04

AI Technical Summary

Technical Problem

There is a lack of effective drugs for Siglec-15-related diseases in the current technology, especially the immune escape problem caused by Siglec-15 as an immunosuppressive checkpoint molecule in the tumor microenvironment, which limits the efficacy of tumor immunotherapy.

Method used

We provide anti-Siglec-15 antibodies and their antigen-binding fragments, which, through high affinity binding to Siglec-15, reverse Siglec-15-induced immunosuppression and regulate immune responses, and can be used to prepare drugs for the treatment of Siglec-15-related diseases and tumors.

Benefits of technology

Anti-Siglec-15 antibodies can specifically bind to Siglec-15, reverse its induced immunosuppression, enhance the immune response, and effectively inhibit tumor growth, especially showing significant efficacy in patients who do not respond to PD-1/PD-L1 immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114437216B_ABST
    Figure CN114437216B_ABST
Patent Text Reader

Abstract

This invention relates to the field of biopharmaceuticals, specifically to an anti-Siglec-15 antibody or its antigen-binding fragment, a nucleic acid sequence encoding the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention, an expression vector containing the nucleic acid sequence, a host cell containing the expression vector, a composition containing the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention, a bispecific antibody or an immune linker linking the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention to a therapeutic agent, and the use of the Siglec-15 antibody or its antigen-binding fragment of the present invention in the preparation of a medicament for treating cancer. The Siglec-15 antibody or its antigen-binding fragment of the present invention can bind to Siglec-15 for the treatment of Siglec-15-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biopharmaceuticals, specifically to an anti-Siglec-15 antibody or its antigen-binding fragment thereof, a nucleic acid sequence encoding the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention, an expression vector containing the nucleic acid sequence, a host cell containing the expression vector, a composition containing the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention, an immune linker linking a bispecific antibody or the anti-Siglec-15 antibody or its antigen-binding fragment of the present invention to a therapeutic agent, and the use of the Siglec-15 antibody or its antigen-binding fragment of the present invention in the preparation of a medicament for treating cancer. Background Technology

[0002] Cancer has become a major killer of human health. Due to factors such as population aging, accelerated industrialization and urbanization, and changes in lifestyle, the incidence and mortality rates of cancer in China continue to rise, and the cancer burden can no longer be ignored. The occurrence and development of cancer is the result of the interaction between genetics and environment, triggered by uncontrolled cell proliferation caused by the malignant transformation of a single cell gene mutation in normal tissue. Cancer treatment requires killing or removing all tumor cells with tolerable side effects for the patient. With the development of techniques such as surgery, radiotherapy, chemotherapy, and targeted therapy, the survival time of many cancer patients has been extended. However, due to tumor metastasis and heterogeneity, most patients develop drug resistance or relapse, ultimately leading to death.

[0003] Over the past decade, a new immunotherapy approach has emerged, represented by immune checkpoint PD-1 / PD-L1 inhibitors. These strategies primarily target tumor immune escape mechanisms. When the PD-1 / PD-L1 pathway is activated in the tumor microenvironment, the anti-tumor immune response of effector T cells is suppressed. Treatment that blocks this pathway can effectively improve the anti-tumor immune response in various tumor types. With the market availability of PD-1 / PD-L1 antibody drugs, tumor immunotherapy has become an emerging treatment paradigm. Compared to radiotherapy, chemotherapy, and targeted therapy, PD-1 / PD-L1 antibody drugs can achieve long-term remission in some patients. The immune system has enormous potential, specifically recognizing and attacking tumor cells without causing toxic side effects to normal tissues. Furthermore, the immune system's memory capacity can prevent tumor recurrence. However, PD-1 / PD-L1 antibody drugs are only effective in 20%-30% of patients. How to enable more patients to benefit from tumor immunotherapy is an urgent problem to be solved. This requires the search for new immune checkpoint therapeutic targets for drug development.

[0004] The sialic acid-binding immunoglobulin-like lectin (Siglec) family is a classic class of immunoglobulin-like agglutinins that mediate cell-cell or pathogen-mediated interactions by recognizing sialic acid-containing glycan structures, playing a crucial regulatory role in innate and adaptive immunity. Currently, 15 human and 9 murine Siglec molecules have been identified, and Siglec is specifically expressed on the surface of myeloid cells and immune cells. Siglec family proteins are type I transmembrane proteins with immunoglobulin superfamily domains. Different family members have varying numbers of "C2-set" immunoglobulin-like domains in their extracellular regions, which show high sequence and folding similarity to immunoglobulin constant regions. The extracellular terminal immunoglobulin domains, called "V-set" domains, show high similarity to antibody variable regions. They also possess transmembrane and intracellular domains. Most Siglec intracellular domains contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thereby exerting immunosuppressive functions.

[0005] Siglec-15 is a highly conserved member of the Siglec family. Its extracellular domain contains two immunoglobulin-like domains, a "C2-set" domain and a "V-set" domain. Its transmembrane domain contains a lysine residue (Lys274, human Siglec-15) that plays a crucial role in interacting with the 12 kDa signaling adaptor molecule DNAX activator protein (DAP12). The interaction between Siglec-15 and DAP12 is via ionic bonds in the transmembrane domain. DAP12 has a very short extracellular domain (<20 amino acids), a transmembrane domain containing an aspartic acid residue (Asp50, human DAP12), and an intracellular domain containing an ITAM (immunoreceptor tyrosine-based activating motif). The ITAM recruits and phosphorylates SYK to transmit signals.

[0006] Early research on Siglec-15 primarily focused on osteoclast-related diseases. Hiruma et al. reported inhibiting the differentiation of RAW264.7 mouse macrophages (often used as an osteoclast precursor model), mouse bone marrow macrophages, and human osteoclast precursors into osteoclasts using polyclonal antibodies against Siglec-15. Ishida-Kitagawa et al. demonstrated that the interaction between Siglec-15 and DAP12, SYK signaling, and the interaction between Siglec-15 and sialylated ligands are crucial for osteoclast differentiation. These in vitro findings were quickly validated in transgenic mice. Hiruma et al. reported that Siglec15-deficient mice exhibited mild trabecular bone sclerosis (increased bone mass) and reduced urinary deoxypyridinium phosphate (a systemic marker of bone resorption), indicating decreased osteoclast viability. Takahata's team also demonstrated these results using another Siglec15-deficient mouse strain.

[0007] Recent studies have found that Siglec-15 is expressed on tumor-associated macrophages and is induced by M-CSF (a cytokine that induces selective activation / polarization of macrophages). Co-culturing sialyl-Tn+ tumor cell lines with M-CSF-induced human macrophages or Siglec-15+ myeloid cells increased the production of TGF-β (a pleiotropic cytokine that promotes epithelial-mesenchymal transition and metastasis in cancer cells), which is dependent on DAP12 and SYK. These results suggest that Siglec-15 may play an important role in the tumor microenvironment.

[0008] On March 5, 2019, Nature Medicine published a new discovery by Professor Chen Lieping's team: Siglec-15 is a novel immunosuppressive checkpoint molecule in the tumor immune microenvironment and a potential target for tumor immunotherapy. The study found that Siglec-15, expressed on the surface of tumor cells or tumor-associated macrophages, interacts with T cell surface receptors, inhibiting T cell tumor-killing activity. Siglec-15 can induce monocytes to differentiate into specific myeloid cells, which inhibit T cell function and promote tumor growth. Further in vitro experiments showed that tumor growth was reduced in mice with Siglec-15 knockout, and treatment with Siglec-15 monoclonal antibodies inhibited tumor growth in mice. Furthermore, the expression of PD-L1 and Siglec-15 is mutually exclusive, suggesting that Siglec-15 antibodies may be effective in patients unresponsive to anti-PD-1 / PD-L1 immunotherapy. These results indicate that Siglec-15 is another molecule involved in immune escape in the tumor microenvironment and has the potential to serve as a therapeutic target.

[0009] There are still unmet needs in the field of cancer therapy. Summary of the Invention

[0010] To overcome the deficiency in existing technologies regarding the lack of drugs for treating Siglec-15-related diseases, this invention provides anti-Siglec-15 antibodies and their use in drug preparation. Anti-Siglec-15 antibodies bind to the Siglec-15 protein and exhibit many desirable properties, including, for example, high affinity binding to the Siglec-15 protein. Furthermore, the antibodies of this invention can reverse Siglec-15-induced inhibition of PBMC proliferation and inhibit Siglec-15 protein-mediated monocyte proliferation, thereby regulating the immune response. Therefore, this invention also relates to methods for regulating immune responses using anti-Siglec-15 antibodies or their antigen-binding fragments. This invention also provides the use of anti-Siglec-15 antibodies or their antigen-binding fragments in the preparation of drugs for treating Siglec-15-related diseases or for treating tumors.

[0011] A first aspect of the present invention provides isolated antibodies binding to Siglec-15 and antigen-binding fragments thereof. In some embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment comprises one or more CDR (antibody complementarity-determining region) sequences selected from the group consisting of: SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 81.

[0012] In another embodiment, it includes one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NO:1, 2, 3, 4, 5, 11, 12, 13, 17, 18, 19, 20, 25, 26, 27, 28, 29, 35, 36, 37, and / or one or more light chain CDR sequences selected from the group consisting of: SEQ ID NO:6, 7, 8, 9, 10, 14, 15, 16, 21, 22, 23, 24, 30, 31, 32, 33, 34, 38, 39, 40, 81.

[0013] In some embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment includes a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 sequences, and / or a light chain variable region comprising LCDR1, LCDR2, and LCDR3 sequences, wherein:

[0014] (a) The heavy chain variable region HCDR1 sequence comprises amino acid sequences selected from SEQ ID NO:1, 11, 17, 25, 35 and their conserved modifications; the heavy chain variable region HCDR2 sequence comprises amino acid sequences selected from SEQ ID NO:2, 3, 4, 12, 18, 19, 26, 27, 28, 36 and their conserved modifications; the heavy chain variable region HCDR3 sequence comprises amino acid sequences selected from SEQ ID NO:5, 13, 20, 29, 37 and their conserved modifications.

[0015] (b) The light chain variable region LCDR1 sequence comprises amino acid sequences selected from SEQ ID NO:6, 7, 14, 21, 30, 31, 38, 81 and their conserved modifications; the light chain variable region LCDR2 sequence comprises amino acid sequences selected from SEQ ID NO:8, 9, 15, 22, 23, 32, 33, 39 and their conserved modifications; the light chain variable region LCDR3 sequence comprises amino acid sequences selected from SEQ ID NO:10, 16, 24, 34, 40 and their conserved modifications.

[0016] (c) The antibody or its antigen-binding fragment binds specifically to Siglec-15.

[0017] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4 and 5, and the light chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 6, 7, 8, 9, 10 and 81.

[0018] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 11, 12 and 13, and the light chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 14, 15 and 16.

[0019] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 17, 18, 19 and 20, and the light chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 21, 22, 23 and 24.

[0020] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 25, 26, 27, 28 and 29, and the light chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 30, 31, 32, 33 and 34.

[0021] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 35, 36 and 37, and the light chain variable region comprises a CDR sequence selected from the group consisting of SEQ ID NO: 38, 39 and 40.

[0022] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:1, the HCDR2 sequence is selected from SEQ ID NO:2, 3, and 4, the HCDR3 sequence is shown in SEQ ID NO:5, the light chain variable region LCDR1 sequence is selected from SEQ ID NO:6, 7, and 8, the LCDR2 sequence is selected from SEQ ID NO:8 and 9, and the LCDR3 sequence is shown in SEQ ID NO:10.

[0023] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:11, the HCDR2 sequence is shown in SEQ ID NO:12, the HCDR3 sequence is shown in SEQ ID NO:13, the light chain variable region LCDR1 sequence is shown in SEQ ID NO:14, the LCDR2 sequence is shown in SEQ ID NO:15, and the LCDR3 sequence is shown in SEQ ID NO:16.

[0024] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:17, the HCDR2 sequence is selected from SEQ ID NO:18 and 19, the HCDR3 sequence is shown in SEQ ID NO:20, the light chain variable region LCDR1 sequence is shown in SEQ ID NO:21, the LCDR2 sequence is selected from SEQ ID NO:22 and 23, and the LCDR3 sequence is shown in SEQ ID NO:24.

[0025] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:25, the HCDR2 sequence is selected from SEQ ID NO:26, 27, and 28, the HCDR3 sequence is shown in SEQ ID NO:29, the light chain variable region LCDR1 sequence is selected from SEQ ID NO:30 and 31, the LCDR2 sequence is selected from SEQ ID NO:32 and 33, and the LCDR3 sequence is shown in SEQ ID NO:34.

[0026] In another embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, wherein the heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:35, the HCDR2 sequence is shown in SEQ ID NO:36, the HCDR3 sequence is shown in SEQ ID NO:37, the light chain variable region LCDR1 sequence is shown in SEQ ID NO:38, the LCDR2 sequence is shown in SEQ ID NO:39, and the LCDR3 sequence is shown in SEQ ID NO:40.

[0027] The antibody or its antigen-binding fragment described in this invention may be a murine antibody, a chimeric antibody, a humanized antibody, a fully human antibody or a fragment thereof, preferably a fully human antibody, a humanized antibody or a fragment thereof.

[0028] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region SEQ ID NO:41 or a variant thereof; and / or a light chain variable region comprising SEQ ID NO:42 or a variant thereof.

[0029] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region SEQ ID NO:43 or a variant thereof; and / or a light chain variable region comprising SEQ ID NO:44 or a variant thereof.

[0030] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region SEQ ID NO:45 or a variant thereof; and / or a light chain variable region comprising SEQ ID NO:46 or a variant thereof.

[0031] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region SEQ ID NO:47 or a variant thereof; and / or a light chain variable region comprising SEQ ID NO:48 or a variant thereof.

[0032] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region SEQ ID NO:49 or a variant thereof; and / or a light chain variable region comprising SEQ ID NO:50 or a variant thereof.

[0033] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:41; and / or a light chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:42.

[0034] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:43; and / or a light chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:44.

[0035] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:45; and / or a light chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:46.

[0036] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:47; and / or a light chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:48.

[0037] In one embodiment, the present invention provides an isolated antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising: a heavy chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:49; and / or a light chain variable region having an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% homology to SEQ ID NO:50.

[0038] A second aspect of the invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, the humanized antibody comprising a mutated heavy chain variable region at one or more sites selected from the following sites of the sequence shown in SEQ ID NO:41: M3, K19, S40, E42, R44, P61, T65, S77, T78, S84, S88, M93, V97, P117 and / or S120 sites, and / or a mutated light chain variable region at one or more sites selected from the following sites of the sequence shown in SEQ ID NO:42: V3, L4, A9, A12, V13, L15, Q17, A19, S22, K24, D32, Q46, P47, E59, I62, A64, N78, H80, P81, V82, E83, E84, A87, A104 and / or L110.

[0039] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region with a mutation introduced at one or more sites selected from the sequence shown in SEQ ID NO:41: M3Q, K19R, S40A, E42G, R44G, P61A, T65K, S77N, T78S, S84N, S88A, M93V, V97A, P117Q and / or S120T, and / or, in SEQ ID NO:41 The sequence shown in NO:42 is a light chain variable region with a mutation introduced at one or more of the following sites: V3Q, L4M, A9S, A12S, V13A, L15V, Q17D, A19V, S22T, K24R, D32E, Q46K, P47A, E59Q, I62V, A64S, N78T, H80S, P81S, V82L, E83Q, E84P, A87F, A104Q and / or L110I.

[0040] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region sequence is selected from SEQ ID NO:51, 53, 55 and 57, and the light chain variable region is selected from SEQ ID NO:52, 54, 56, 58 and 82.

[0041] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, the humanized antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:51 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:52 or a variant thereof.

[0042] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:53 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:54 or a variant thereof.

[0043] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:55 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:56 or a variant thereof.

[0044] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:57 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:58 or a variant thereof.

[0045] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:53 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:56 or a variant thereof.

[0046] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:53 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:58 or a variant thereof.

[0047] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:53 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:82 or a variant thereof.

[0048] A third aspect of the invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region with a mutation introduced at one or more sites selected from the following sites of the sequence shown in SEQ ID NO:45: E1, Q5, L11, V12, R13, L20, T23, K38, R40, T41, E42, A61, P62, K67, A68, A72, S76, N77, L81, H82, T85, T87, V97 and / or S113 sites, and / or a light chain variable region with a mutation introduced at one or more sites selected from the following sites of the sequence shown in SEQ ID NO:46: S8, F12, A18, Y36, L41, P43, K45, V47, T58, D74, G78, N81, I82, P84 and / or V89 sites.

[0049] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region with a mutation introduced at one or more sites selected from the sequence shown in SEQ ID NO:45: E1Q, Q5V, L11V, V12K, R13K, L20V, T23K, K38R, R40A, T41P, E42G, A61S, P62Q, K67R, A68V, A72R, S76T or S76A, N77S, L81M, H82E, T85S, T87R, V97A and / or S113T sites, and / or in SEQ ID NO:45. The sequence shown in NO:46 is a light chain variable region with a mutation introduced at one or more of the following sites: S8P, F12A, A18V, Y36H, L41E, P43G, K45R, V47L, T58K, D74E, G78T, N81S, I82L, P84S and / or V89D sites.

[0050] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region sequence is selected from SEQ ID NO:59, 61, 63 and 65, and the light chain variable region is selected from SEQ ID NO:60, 62, 64 and 66.

[0051] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:59 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:60 or a variant thereof.

[0052] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:61 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:62 or a variant thereof.

[0053] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:63 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:64 or a variant thereof.

[0054] A fourth aspect of the invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region with a mutation introduced at one or more sites selected from the sequence shown in SEQ ID NO:47: E1, Q5, P9, V10, L11, V12, M20, E23, K38, S40, K43, S44, N61, K67, A68, L70, V72, S76, N84, T87, S91 and / or S119 sites, and / or in SEQ ID NO:47. The sequence shown in NO:48 is a light chain variable region with mutations introduced at one or more of the following sites: V3, L4, A9, A12, V13, L15, Q17, A19, S22, R43, R46, P47, E59, I62, A64, R72, D80, P81, V82, E83, A84, D85, V87, A104 and / or L110 sites.

[0055] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region with a mutation introduced at one or more sites selected from the sequence shown in SEQ ID NO:47: E1Q, Q5V, P9A, V10E, L11V, V12K, M20V, E23K, K38R, S40A, K43Q, S44G, N61A, K67R, A68V, L70M, V72R, S76T, N84S, T87R, S91T and / or S119T sites, and / or in SEQ ID NO:47. The sequence shown in NO:48 contains a light chain variable region with a mutation introduced at one or more of the following sites: V3Q, L4M, A9S, A12S, V13A, L15V, Q17D, A19V, S22T, R43K, R46K, P47A, E59Q, I62V, A64S, R72G, D80S, P81S, V82L, E83Q, A84P, D85E, V87F, A104Q, and / or L110I.

[0056] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region sequence is selected from SEQ ID NO:67, 69, 71 and 73, and the light chain variable region is selected from SEQ ID NO:68, 70, 72 and 74.

[0057] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:67 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:68 or a variant thereof.

[0058] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:69 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:70 or a variant thereof.

[0059] In one embodiment, the present invention provides an isolated humanized antibody or antigen-binding fragment thereof that binds to Siglec-15, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region sequence comprises the sequence shown in SEQ ID NO:71 or a variant thereof, and the light chain variable region sequence comprises the sequence shown in SEQ ID NO:72 or a variant thereof.

[0060] In any of the above embodiments, the antibody of the present invention or a variant of its antigen-binding fragment may contain one, two or three conserved modified amino acid substitutions.

[0061] In any of the above embodiments, the present invention uses "uppercase letter + number" to represent the amino acid residue at the specified position. "uppercase letter 1 + number + uppercase letter 2" indicates that the amino acid residue at the specified position is replaced by another amino acid residue. For example, "E1" represents that the amino acid residue at position 1 is glutamic acid, "E1Q" represents that the glutamic acid residue at position 1 is replaced by glutamine, "Q5" represents that the amino acid residue at position 5 is glutamine, and "Q5V" represents that the glutamine residue at position 5 is replaced by valine.

[0062] In any of the above embodiments, the antibody or antigen-binding fragment of the present invention may comprise: a human heavy chain constant region or a variant thereof, wherein the variant comprises up to 20 conserved modified amino acid substitutions; and / or a human light chain constant region or a variant thereof, wherein the variant comprises up to 20 conserved modified amino acid substitutions. In some embodiments, the variant may comprise up to 10 conserved modified amino acid substitutions. In some embodiments, the variant may comprise up to 5 conserved modified amino acid substitutions. In some embodiments, the variant may comprise up to 3 conserved modified amino acid substitutions. In any of the above embodiments, the human heavy chain constant region or a variant thereof may be a constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD or a variant thereof, preferably the IgG1 or IgG4 constant region or a variant thereof.

[0063] The amino acid residues in the antibodies or antigen-binding fragments of this invention are numbered using the EU indexing method of Kabat.

[0064] In any of the above embodiments, the antibody or its antigen-binding fragment of the present invention can bind Siglec-15 at a KD of 930 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 614 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 325 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 202 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 109 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 85.6 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 80.6 pM or lower. In another embodiment, the antibody or its antigen-binding fragment can bind Siglec-15 at a KD of 72.4 pM or lower. In another embodiment, the antibody or its antigen-binding fragment may bind to Siglec-15 at a KD of 68.3 pM or lower.

[0065] The KD value can be measured using any effective method. In a preferred embodiment, the dissociation constant is measured using bioluminescence interferometry (e.g., the ForteBio Octet method described in Example 2). In other preferred embodiments, the dissociation constant can be measured using surface plasmon resonance techniques (e.g., Biacore) or Kinexa.

[0066] In some embodiments, the antibody-antigen binding fragments of the present invention include, but are not limited to, antibody fragments of Fab, Fab', F(ab')2, Fv, or scFv, sdFv (disulfide-linked Fv).

[0067] In this invention, the Fab fragment is a monovalent fragment composed of VL, VH, CL, and CH1 domains; the F(ab')2 fragment is a divalent fragment containing two Fab fragments connected by a disulfide bridge in the hinge region; the Fd fragment is composed of VH and CH1 domains; the Fv fragment is composed of the VL and VH domains of the antibody single arm; and the scFv fragment is a monovalent molecule formed by pairing VL and VH regions.

[0068] In some embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment can bind to human Siglec-15. In other embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment can bind to monkey Siglec-15. In still other embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment can bind to mouse Siglec-15.

[0069] In some embodiments, the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment may have the same or different epitopes that Siglec-15 binds to.

[0070] In some embodiments, the antibody fragment of the present invention is a bispecific antibody.

[0071] The fifth aspect of the invention also includes a bispecific antibody comprising any one of the antibodies that bind to Siglec-15 described above or their antigen-binding fragments.

[0072] The sixth aspect of the invention also includes a nucleic acid sequence encoding the anti-Siglec-15 antibody of the present invention and its antigen-binding fragment.

[0073] The seventh aspect of the invention also includes an expression vector comprising a nucleic acid sequence encoding an antibody of the invention or an antigen-binding fragment thereof.

[0074] The eighth aspect of the invention also includes a host cell comprising the expression vector described in the seventh aspect.

[0075] Furthermore, the ninth aspect of the invention also includes a method for preparing the antibody of the invention or its antigen-binding fragment, the method comprising: (a) culturing a host cell containing a nucleic acid encoding the antibody of the invention or its antigen-binding fragment in a culture medium under conditions that allow the nucleic acid sequence to be expressed, thereby producing a polypeptide comprising a light chain and a heavy chain variable region; and (b) recovering the polypeptide from the host cell or the culture medium.

[0076] The tenth aspect of the invention also includes a composition comprising an antibody of the invention or an antigen-binding fragment thereof, which can be combined with a pharmaceutically acceptable carrier or diluent.

[0077] The eleventh aspect of the invention further includes an immunolinker comprising the anti-Siglec-15 antibody of the present invention or an antigen-binding fragment thereof linked to a therapeutic agent (e.g., a bacterial toxin or a radiotoxin). Non-limiting examples of cytotoxic agents include: taxol, cytochalasin B, mitomycin, etoposide, and vincristine or other antimetabolites, alkylating agents, antibiotics, and antimitotic drugs. The twelfth aspect of the invention further includes the use of the anti-Siglec-15 antibody of the first aspect or an antigen-binding fragment thereof, the composition of the tenth aspect, the immunolinker of the eleventh aspect, and the bispecific antibody of the fifth aspect in the preparation of a medicament for treating Siglec-15-related diseases.

[0078] Alternatively, the anti-Siglec-15 antibody or its antigen-binding fragment described in the first aspect of the present invention, the composition described in the tenth aspect, the immune linker described in the eleventh aspect, and the bispecific antibody described in the fifth aspect may be used to treat Siglec-15-related diseases.

[0079] Alternatively, a method of treating Siglec-15-related diseases comprising administering to a subject in need the anti-Siglec-15 antibody or its antigen-binding fragment as described in the first aspect of the invention, the composition as described in the tenth aspect, the immune linker as described in the eleventh aspect, or the bispecific antibody as described in the fifth aspect.

[0080] The Siglec-15-related diseases described in this invention include, but are not limited to, cancer or bone-related diseases. The cancer or bone-related diseases can be Siglec-15-positive cancers and bone diseases.

[0081] The cancers mentioned include, but are not limited to, leukemia, melanoma, head and neck cancer, glioblastoma cells, breast cancer, ovarian cancer, gastric cancer, urothelial carcinoma, gastroesophageal cancer, esophageal cancer, endometrial cancer, colon cancer, liver cancer, lung cancer, or bladder cancer; wherein the leukemias mentioned include acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphoblastic leukemia (CLL), and chronic myelogenous leukemia (CML);

[0082] The bone diseases mentioned include, but are not limited to, osteoporosis, bone loss, osteoarthritis, and osteomalacia.

[0083] The present invention also includes the use of the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment in the preparation of a drug for reversing Siglec-15-hFc-mediated inhibition of PBMC proliferation.

[0084] The present invention also includes the use of the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment thereof in the preparation of a medicament for inhibiting Siglec-15 protein-mediated monocyte proliferation.

[0085] The present invention also includes the use of the anti-Siglec-15 antibody of the present invention or an antigen-binding fragment thereof in the preparation of a medicament for inhibiting Siglec-15 protein-mediated monocyte survival.

[0086] The present invention also includes the use of the anti-Siglec-15 antibody of the present invention or its antigen-binding fragment in the preparation of a medicament for regulating an immune response.

[0087] The thirteenth aspect of the present invention also includes the use of the anti-Siglec-15 antibody or its antigen-binding fragment described in the first aspect of the present invention, the composition described in the tenth aspect, the immune linker described in the eleventh aspect, and the bispecific antibody described in the fifth aspect in the preparation of a medicament for inhibiting tumor cell growth.

[0088] Alternatively, the anti-Siglec-15 antibody or its antigen-binding fragment described in the first aspect of the present invention, the composition described in the tenth aspect, the immune linker described in the eleventh aspect, and the bispecific antibody described in the fifth aspect may be used to inhibit tumor cell growth.

[0089] Alternatively, a method for inhibiting tumor cell growth includes administering to a subject in need the anti-Siglec-15 antibody or its antigen-binding fragment as described in the first aspect of the invention, the composition as described in the tenth aspect, the immune linker as described in the eleventh aspect, or the bispecific antibody as described in the fifth aspect.

[0090] In some implementations, the anti-Siglec-15 antibody or its antigen-binding fragment may be combined with a second therapeutic agent or form of treatment.

[0091] In one implementation, treatment with an anti-Siglec-15 antibody or its antigen-binding fragment may be combined with chemotherapy.

[0092] In one implementation, treatment with an anti-Siglec-15 antibody or its antigen-binding fragment may be combined with radiotherapy.

[0093] In some implementations, the anti-Siglec-15 antibody or its antigen-binding fragment may be combined with another therapeutic antibody used to treat cancer.

[0094] The positive and progressive effects of this invention are as follows:

[0095] This invention provides a novel antibody or antigen-binding fragment with high affinity for Siglec-15, its preparation method, a composition or immunolinker containing it, or a bispecific antibody. This invention provides a method for regulating immune responses with anti-Siglec-15 antibody or its antigen-binding fragment, and also has a therapeutic effect on tumors. Attached Figure Description

[0096] Figure 1 The binding curve and EC50 value of the anti-Siglec-15 chimeric antibody to 293T-hu-S15 are shown.

[0097] Figure 2A The image shows the reversal curve and EC50 value of the inhibition of PBMC proliferation induced by the chimeric antibody 21F6C6 against Siglec-15 protein.

[0098] Figure 2B The image shows the reversal curve and EC50 value of the inhibition of PBMC proliferation induced by the chimeric antibody 75E1F2 against Siglec-15 protein.

[0099] Figure 2C The image shows the reversal curve and EC50 value of the inhibition of PBMC proliferation induced by the chimeric antibody 174C11C9 on Siglec-15 protein.

[0100] Figure 2D The image shows the reversal curve and EC50 value of the inhibition of PBMC proliferation induced by the chimeric antibody 124B11F6 against Siglec-15 protein.

[0101] Figure 2E The image shows the reversal curve and EC50 value of the inhibition of PBMC proliferation induced by the chimeric antibody 255C12B10 against Siglec-15 protein.

[0102] Figure 3 The anti-Siglec-15 chimeric antibody was used to inhibit Siglec-15 protein-mediated monocyte proliferation.

[0103] Figure 4A The design diagram for humanization of the variable region of the heavy chain of the 21F6C6 chimeric antibody.

[0104] Figure 4B The design diagram for the humanization of the variable region of the light chain of the 21F6C6 chimeric antibody.

[0105] Figure 4CThis is a design diagram for the humanization of the variable region of the heavy chain of the 124B11F6 chimeric antibody.

[0106] Figure 4D This is a design diagram for the humanization of the variable region of the light chain of the 124B11F6 chimeric antibody.

[0107] Figure 4E This is a design diagram for the humanization of the variable region of the heavy chain of the 174C11C9 chimeric antibody.

[0108] Figure 4F This is a design diagram for the humanization of the variable region of the light chain of the 174C11C9 chimeric antibody.

[0109] Figure 5A The percentage curves and EC50 values ​​of the humanized antibodies 21F6C6-hH1L1 and 21F6C6-hH2L2 reversing Siglec-15 protein-mediated inhibition of PBMC proliferation.

[0110] Figure 5B The percentage curves and EC50 values ​​of the humanized antibodies 21F6C6-hH2L3 and 21F6C6-hH3L3 reversing Siglec-15 protein-mediated inhibition of PBMC proliferation.

[0111] Figure 5C The percentage curves and EC50 values ​​of the humanized antibodies 21F6C6-hH2L4 and 21F6C6-hH4L4 reversing the inhibition of PBMC proliferation mediated by Siglec-15 protein.

[0112] Figure 5D The percentage curves and EC50 values ​​of the humanized antibodies 124B11F6-hH1L1, 124B11F6-hH2L2, and 124B11F6-hH3L3 reversing Siglec-15 protein-mediated inhibition of PBMC proliferation.

[0113] Figure 5E The percentage curves and EC50 values ​​of the humanized antibodies 174C11C9-hH1L1, 174C11C9-hH2L2, and 174C11C9-hH3L3 reversing Siglec-15 protein-mediated inhibition of PBMC proliferation.

[0114] Figure 6 A diagram illustrating the inhibition of Siglec-15 protein-mediated monocyte proliferation by anti-Siglec-15 humanized antibody.

[0115] Figure 7 The growth curves of tumor volume in the control and treatment groups of mice in the MC38-hSiglec15 tumor model are shown.

[0116] Figure 8The curves showing the change in body weight over time in the control and treatment groups of the MC38-hSiglec15 tumor model. Detailed Implementation

[0117] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed according to conventional methods and conditions, or as selected according to the product instructions.

[0118] Example 1: Preparation of Siglec-15 antigen and detection protein

[0119] Using the extracellular region (F20-F263) of human Siglec-15 (UniProt Sialic acid-binding Ig-like lectin 15Isoform 1) as a template, the gene sequence encoding the antigen and detection protein of this invention was obtained. This sequence was then recombined with an antibody heavy chain Fc fragment (such as human IgG1) or a His tag, and purified by expression in HEK293 or Expi293 cells to obtain the antigen and detection protein of this invention. The protein manufacturer is Beijing Baipusaisi Biotechnology Co., Ltd., with catalog numbers SG5-H5253 (Fc tag) and SG5-H52H3 (His tag), respectively. The extracellular region sequence of human Siglec-15 is shown in SEQ ID NO:75, where amino acid residues 1-19 form the signal peptide sequence, amino acid residues 40-158 form the "V-set" domain, and amino acid residues 168-251 form the "C2-set" domain. The full-length extracellular region of human Siglec-15 is recombined with human IgG1. The recombinant protein sequence obtained by linking the Fc fragment (hS15-hFc) is shown in SEQ ID NO:76, where amino acid residues 1-244 are the full-length extracellular region of Siglec-15, and amino acid residues 253-483 are the human IgG1 Fc sequence. The recombinant protein sequence obtained by linking the first domain of Siglec-15 (Domain 1, containing the "V-set" domain) to human IgG1 Fc (hS15-D1-hFc) is shown in SEQ ID NO:77, where amino acid residues 1-4 are the signal peptide sequence, amino acid residues 5-152 are the first domain of Siglec-15 (where amino acid residues 25-143 are the Siglec-15 "V-set" domain sequence), amino acid residues 153-159 are the linker sequence, and amino acid residues 160-390 are the human IgG1 Fc sequence. The protein sequence obtained by linking the full-length extracellular region of human Siglec-15 to the His tag sequence is shown in SEQ ID NO:77. As shown in SEQ ID NO:78, amino acid residues 1-244 represent the full-length extracellular region sequence of human Siglec-15, and amino acid residues 253-262 represent the His tag sequence. The mouse and cynomolgus monkey Siglec-15 proteins used for detection were commercially available products purchased from Beijing Baipusaisi Biotechnology Co., Ltd., with catalog numbers SG5-M52H7 and SG5-C52H6, respectively. The protein sequence obtained by linking the full-length extracellular region of cynomolgus monkey Siglec-15 with the His tag sequence is shown in SEQ ID NO:79, where amino acid residues 1-244 represent the full-length extracellular region sequence of monkey Siglec-15, and amino acid residues 253-262 represent the His tag sequence.The protein sequence obtained by linking the full-length extracellular region of mouse Siglec-15 with the His tag sequence is shown in SEQ ID NO:80, where amino acid residues 1-239 are the full-length extracellular region sequence of mouse Siglec-15, and amino acid residues 248-257 are the His tag sequence.

[0120] Example 2: Preparation of anti-human Siglec-15 hybridoma monoclonal antibody

[0121] Fifteen mice (5 C57bl / 6, 5 blb / c, and 5 SJL) were immunized with adjuvanted emulsified hS15-hFc. Two weeks later, they were immunized again with either hS15-hFc or hS15-D1-hFc. Serum was collected for ELISA to assess antiserum titers. Mice with higher serum titers were selected for spleen cell fusion. Three days after the final booster immunization, spleen cells were collected for fusion. Five rounds of fusion were performed using electrofusion, and the hybridoma cells obtained after each fusion were seeded into 50 96-well plates. The hybridoma supernatant was subjected to binding activity assays to screen for positive clones, which were then further subcloned. Positive clones were selected through binding activity assays and in vitro immune cell function assays and sequenced.

[0122] Results: Five positive hybridoma clones were obtained by combining activity assays and in vitro immune cell function assays, namely 21F6C6, 75E1F2, 124B11F6, 174C11C9 and 255C12B10. The heavy chain variable region and light chain variable region sequences of the five hybridoma clones are shown below.

[0123] 21F6C6:

[0124] Heavy chain variable region sequence (SEQ ID NO:41):

[0125] EVMLVESGGGLVKPGGSLKLSCAASGFTFS SYAMS WVRQSPEKRLEWVA TISSGGSLIYYPDSVTG RFTISRDNAKSTLYLQMSSLRSEDTAMYYCVR HGYYYGDSTLYYAMDY WGPGTSVTVSS

[0126] The underlined sequences above are HCDR1, HCDR2, and HCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:1, 2, and 5, respectively. SEQ ID NO:3 and 4 are obtained by substituting one or two amino acids in SEQ ID NO:2.

[0127] Light chain variable region sequence (SEQ ID NO:42):

[0128] DIVLTQSPASLAVSLGQRATISC KASQSVDYDGDSYMN WYQQKPGQPPKLLIY AASNLES GIPARFSGSGSGTDFTLNIHPVEEEDAATYYC QQSNEAPLT FGAGTKLELK

[0129] The underlined sequences above are LCDR1, LCDR2, and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:6, 8, and 10, respectively. SEQ ID NO:7 and 9 are obtained by substituting one amino acid into SEQ ID NO:6 and 8, respectively.

[0130] 75E1F2:

[0131] Heavy chain variable region sequence (SEQ ID NO:43):

[0132] EVQLVESGGGSVKPGGSLKLSCAASGFTFS DYGMH WVRQAPEKGLEWIT YISSGSSIIDYSDTVKG RFTISRDNAKDTLFLQMTSLRSEDTAIYYCVR REDHYAMDY WGQGTSVTVSS

[0133] The underlined sequences above are HCDR1, HCDR2 and HCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:11, 12 and 13, respectively.

[0134] Light chain variable region sequence (SEQ ID NO:44):

[0135] DIVMTQSHKFLSTSVGDRVSITC KASQDVYTAVA WFQQKPGQSPKLLFY SASYRF TGVPDRFNGSGSGTDFTLTITSMQAEDLAVYYC QQHYSTPWT FGGGTKLEIK

[0136] The underlined sequences above are LCDR1, LCDR2 and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:14, 15 and 16, respectively.

[0137] 124B11F6:

[0138] Heavy chain variable region sequence (SEQ ID NO:45):

[0139] EVQLQQSGAELVRPGASVKLSCTASVFNIK DYYMHWVKQRTEQGLEWIG RIDP E DDKTKYAPKFQG KATITADTSSNTAYLHLSTLTSEDTAVYYCVR GWLGYIMDF WGQGTSVTVSS

[0140] The underlined sequences above are HCDR1, HCDR2, and HCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:17, 18, and 20, respectively. SEQ ID NO:19 is obtained by substituting two amino acids into SEQ ID NO:18.

[0141] Light chain variable region sequence (SEQ ID NO:46):

[0142] QLVLTQSSSASFSLGASAKLTC TLSSQHSTYTID WYQQQPLKPPKYVME LKEDGSHSTGD GIPDRFSGSSSGADRYLGISNIQPEDEAVYIC GVGATIKEQFVYV FGGGTKVTVL

[0143] The underlined sequences above are LCDR1, LCDR2, and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:21, 22, and 24, respectively. SEQ ID NO:23 is obtained by substituting one amino acid into SEQ ID NO:22.

[0144] 174C11C9:

[0145] Heavy chain variable region sequence (SEQ ID NO:47):

[0146] EVQLQQSGPVLVKPGASVKMSCEASGYIFT DYYMN WVKQSPGKSLEWIG VFNPYSGGISYNQKFKG KATLTVDTSSSTAYMELNSLTSEDSAVYYCAR DYYYLSSHGFYALDY WGQGTSVTVSS

[0147] The underlined sequences above are HCDR1, HCDR2, and HCDR3, respectively, with amino acid sequences shown in SEQ ID NO:25, 26, and 29. SEQ ID NO:27 and 28 are obtained by substituting one or two amino acids in SEQ ID NO:26. Light chain variable region sequence (SEQ ID NO:48):

[0148] DIVLTQSPASLAVSLGQRATISC RASESVDSYGNSFIH WYQQRPGRPPKLLMY RASNLES GIPARFSGSGSRTDFTLTIDPVEADDVATYYC QQSNEDPLT FGAGTKLELK

[0149] The underlined sequences above are LCDR1, LCDR2, and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:30, 32, and 34, respectively. SEQ ID NO:31 and 33 are obtained by substituting one amino acid into SEQ ID NO:30 and 32, respectively.

[0150] 255C12B10:

[0151] Heavy chain variable region sequence (SEQ ID NO:49):

[0152] EVQLQQSGPELVKPGASVKMSCKASGYTFT GYNMN WVKQSHGKSLEWIG YINPNNGGTRYNQKFKG KATLTINKSSSTAYMELRRSLTSEDSAVYYCAR DYGIDY WGQGTTLTVSS

[0153] The underlined sequences above are HCDR1, HCDR2 and HCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:35, 36 and 37, respectively.

[0154] Light chain variable region sequence (SEQ ID NO:50):

[0155] EIQMTQSPSSMSASLGDRITITC QATQDIVKNLN WYQQKPGKPPSFLIY YATELAE GVPSRFSGSGSGSDYSLTISNLESEDFADYYC LQFYEFPYT FGGGTKLEIK

[0156] The underlined sequences above are LCDR1, LCDR2 and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:38, 39 and 40, respectively.

[0157] Note: In the above sequences, the underlined sequences are CDR1, CDR2, and CDR3 of the heavy chain variable region or the light chain variable region, respectively. Separated by the three CDR sequences are the four frame region sequences of the heavy chain variable region or the light chain variable region, FWR1, FWR2, FWR3, and FWR4. The specific CDR sequences and their numbers for the antibody are shown in Table 1 below.

[0158] Table 1. CDR sequence information of antibodies

[0159]

[0160]

[0161] Example 3: Binding of anti-human Siglec-15 antibody to Siglec-15 protein from different species

[0162] Chimeric antibodies were synthesized by combining the variable region of the hybridoma-selected antibody with the constant region of human IgG1 (N297A), and named 21F6C6, 75E1F2, 124B11F6, 174C11C9, and 255C12B10, respectively. Binding activity experiments were conducted on Siglec-15 proteins from different species with the chimeric antibodies. The Siglec-15 proteins from human, mouse, and cynomolgus monkeys were obtained from Beijing Baipusaisi Biotechnology Co., Ltd. Antigen was coated at 0.5 μg / ml, and antibodies were serially diluted from 1 μg / ml and incubated with the antigen. Horseradish peroxidase-labeled anti-human IgG antibody was used as the secondary antibody. OD was read after substrate addition. 450 value.

[0163] Results: All five anti-Siglec-15 chimeric antibodies showed binding activity to both human and cynomolgus monkey Siglec-15. Among them, the chimeric antibodies derived from hybridomas 124B11F6, 174C11C9, and 255C12B10 showed binding activity to mouse Siglec-15. Table 2 shows the EC50 results of the anti-Siglec-15 chimeric antibodies binding to Siglec-15 antigens from different species. 50 value.

[0164] Table 2. ECG binding of anti-Siglec-15 chimeric antibodies to Siglec-15 antigen from different species 50 value

[0165]

[0166]

[0167] Example 4: Binding of anti-human Siglec-15 antibody to cells expressing human Siglec-15

[0168] HEK293T cell lines overexpressing human Siglec-15 were purchased from Kangyuan Bochuang (HEK293T-hu-S15 cell line, catalog number KC-1314). Purified anti-Siglec-15 chimeric antibody was serially diluted at 100 nM and incubated with HEK293T-hu-S15 cell lines at 4°C for 30 minutes. Anti-human IgG (Fc specific)-FITC (catalog number: F9512) secondary antibody was added to the sample and incubated for 30 minutes. The cells were then analyzed by flow cytometry.

[0169] Results: All five anti-Siglec-15 chimeric antibodies bound to the HEK293T-hu-S15 cell line. Figure 1 The binding curves and EC50 values ​​of the anti-Siglec-15 chimeric antibody and HEK293T-hu-S15 are shown.

[0170] Example 5: Affinity assessment of recombinant antibody to Siglec-15 protein

[0171] Affinity analysis was performed using the Biacore 8K chip. Anti-human Fc antibodies were immobilized on the CM5 chip to capture the test antibodies. The test antibody stock solution was diluted to 5 μg / mL and sequentially injected into approximately 500 RU of the experimental channel at a flow rate of 10 μL / min. The analyte was Human Siglec-15, His Tag (Cat. No. SG5-H52H3). The diluted human Siglec-15 protein was sequentially injected into the experimental and reference channels at a flow rate of 30 μL / min, with a binding time of 150 s and a dissociation time of 700 s. The KD value of each antibody was calculated using the Biacore 8K analysis software.

[0172] Results: Table 3 shows the affinity analysis results between the anti-Siglec-15 chimeric antibody and the Siglec-15 protein.

[0173] Table 3. Affinity analysis results of anti-Siglec-15 chimeric antibody and Siglec-15 protein.

[0174] Antibody name ka(1 / Ms) kd(1 / s) KD(M) 21F6C6 chimeric antibody 3.95E+06 1.87E-04 4.73E-11 174C11C9 chimeric antibody 1.21E+06 3.70E-04 3.05E-10 75E1F2 chimeric antibody 8.41E+05 7.82E-04 9.30E-10 124B11F6 chimeric antibody 1.02E+05 1.46E-07 1.43E-12 255C12B10 chimeric antibody 2.96E+05 1.58E-04 5.36E-10

[0175] Example 6: Identification of chimeric antibody epitopes

[0176] Epitope competition experiments were performed on the test antibodies using the Octet RED96e (ForteBio) instrument. Human Siglec-15,His Tag (Cat. No. SG5-H52H3) (5 μg / mL) was captured using the HIS1K biosensor and bound to the primary antibody (100 nM) for 180 s. Then, the Human Siglec-15,His Tag (antigen) – primary antibody and secondary antibody (100 nM) were bound together on the biosensor for 90 s. Data were analyzed using the Octet RED96e (ForteBio) analysis software.

[0177] Results: Table 4 shows the competition parameters between anti-Siglec-15 chimeric antibodies. 60%-100% indicates no competition, indicating that the antigenic epitopes are inconsistent or partially consistent; 20%-60% indicates partial competition, indicating that the antigenic epitopes are partially consistent; <20% indicates complete competition, indicating that the antigenic epitopes are consistent.

[0178] Table 4. Competition parameters between anti-Siglec-15 chimeric antibodies

[0179]

[0180] Note: Shaded cells represent self-reaction control results.

[0181] Example 7: Anti-Siglec-15 chimeric antibody can reverse Siglec-15 protein-mediated inhibition of PBMC proliferation.

[0182] Resuscitate frozen peripheral blood mononuclear cells (PBMCs), serially dilute anti-Siglec-15 chimeric antibody and hS15-hFc protein (0.5 μg / ml), incubate at 37°C for 30 minutes, then add 1×10 5 PBMC cells and soluble OKT3 (0.5 ng / ml, eBioscience) were cultured for 3 days, and then celltiterglo (Promega) was added. Fluorescence values ​​were read to evaluate cell proliferation.

[0183] Results: All five anti-Siglec-15 chimeric antibodies could reverse hS15-hFc-mediated PBMC proliferation inhibition. Figure 2A -E represents the percentage curves of inhibition recovery for antibodies 21F6C6, 75E1F2, 174C11C9, 124B11F6, and 255C12B10, as well as their EC50 values.

[0184] Example 8: Anti-Siglec-15 chimeric antibody can inhibit Siglec-15 protein-mediated monocyte survival.

[0185] Cryopreserved CD14+ monocytes isolated from human PBMCs were revived, and after incubation at 37°C for 30 minutes with different concentrations of anti-Siglec-15 chimeric antibody and hS15-hFc protein, 1×10⁻⁶ ppm of anti-Siglec-15 chimeric antibody was added. 5 CD14+ mononuclear cells. After 6 days of culture, XTT (Roche, catalog number 11465015001) was added to the culture plate, and after 2 hours of culture, OD450-OD690 were read to measure cell viability.

[0186] result: Figure 3 The hS15-hFc protein shown can induce the survival and proliferation of CD14+ monocytes, and the anti-Siglec-15 chimeric antibody can inhibit the Siglec-15 protein-mediated monocyte proliferation in a gradient manner.

[0187] Example 9: Humanization of anti-Siglec-15 antibody

[0188] The chimeric antibodies 21F6C6, 124B11F6, and 174C11C9 were humanized to provide four heavy chains and four light chains, respectively, as shown in Table 5 below.

[0189] Table 5 Humanization design of chimeric antibodies

[0190]

[0191] Results: The humanized sequence design for 21F6C6 is shown in [link to documentation]. Figure 4A and Figure 4B The humanized sequence design of 124B11F6 can be found in [link to design]. Figure 4C and Figure 4D The humanized sequence design of 174C11C9 can be found in [link to design]. Figure 4E and Figure 4F The gray-shaded areas represent mouse-derived sequences, the bolded slanted areas represent CDR region sequences, the black-shaded areas represent humanized sequences, and the remaining areas represent original human-derived sequences. Figures 4A-4F In the text, the abbreviation "hu" for humanized antibody has the same meaning as "h" in Table 5 and can be used interchangeably; this principle can be applied to the present invention.

[0192] Example 10: Affinity assessment of humanized antibody against Siglec-15 protein

[0193] Different combinations of humanized sequences 21F6C6, 124B11F6, and 174C11C9 were expressed (Table 6). A point mutation was performed on LCDR1 of 21F6C6-hH2L4 to obtain the humanized antibody 21F6C6-hH2L4V, which removed the isomerization post-translational modification site. Its light chain variable region sequence is SEQ ID NO:82 (21F6C6-hH2L4V), and the LCDR1 sequence is shown in SEQ ID NO:81 (21F6C6-hH2L4V).

[0194] Affinity analysis was performed using Biacore. Anti-human Fc antibodies were immobilized on a CM5 chip to capture the analyte, Siglec-15 protein. (Method same as in Example 6)

[0195] Results: Table 6 shows the affinity analysis results between the humanized antibody and the Siglec-15 protein.

[0196] Table 6. Affinity analysis results between humanized antibodies and Siglec-15 protein.

[0197]

[0198] Among them, 21F6C6-mHL represents the chimeric antibody 21F6C6 composed of the mouse anti-variable region and hIgG1 (174C11C9-mHL and 124B11F6-mHL are similar), and 21F6C6-hH1L1 represents Figure 4A The human-centered design of huVH1 and Figure 4B Humanized antibodies were obtained by recombining huVL1 with the heavy chain constant region of hIgG1 and the light chain constant region of Kappa, respectively. 124B11F6-hH1L1 represents... Figure 4C The human-centered design of huVH1 and Figure 4D Humanized antibodies were obtained by recombining huVL1 with the constant region of hIgG1 and the constant region of the Lambda-C2 light chain, respectively. 174C11C9-hH2L2 represents... Figure 4E The human-centered design of huVH2 and Figure 4F Humanized antibodies were obtained by recombination of huVL2 with the constant region of hIgG1 and the constant region of the Kappa light chain, respectively. Other antibodies were obtained similarly.

[0199] Example 11: Humanized antibodies can reverse Siglec-15-mediated inhibition of PBMC proliferation.

[0200] Resuscitate frozen peripheral blood mononuclear cells (PBMCs), serially dilute anti-Siglec-15 humanized antibody and hS15-hFc protein (1 μg / ml), incubate at 37°C for 30 minutes, then add 1×10 5 PBMC cells and soluble OKT3 (5 ng / ml, eBioscience) were cultured for 3 days, and then celltiterglo (Promega) was added. Fluorescence values ​​were read to evaluate cell proliferation.

[0201] Results: The anti-Siglec-15 humanized antibody can reverse hS15-hFc-mediated inhibition of PBMC proliferation. Figure 5A -E represents the percentage curve of antibody reversion inhibition and EC. 50 value.

[0202] Example 12: Anti-Siglec-15 humanized antibody can inhibit Siglec-15-mediated monocyte survival.

[0203] Cryopreserved CD14+ monocytes isolated from human PBMCs were revived, and after incubation at 37°C for 30 minutes with anti-Siglec-15 humanized antibody (10 μg / ml) and hS15-hFc protein (2 μg / ml), 1×10⁻⁶ mol / L of anti-Siglec-15 humanized antibody was added. 5 10 CD14+ mononuclear cells. After 5 days of culture, Celltiterglo (Promega) was added to the culture plate, and the fluorescence value was read to measure cell viability.

[0204] result: Figure 6 The humanized anti-Siglec-15 antibody shown can inhibit Siglec-15 protein-mediated monocyte proliferation.

[0205] Example 13: Evaluation of the antitumor efficacy of anti-Siglec-15 humanized antibody in the HuCELL tumor model

[0206] The experimental animals were humanized SIGLEC15 C57BL / 6J mice (C57BL / 6J-SIGLEC15HuGEMM), female, 6–8 weeks old (mice's age at tumor inoculation), weighing 18–24 g (mice's weight at grouping), a total of 50 mice (32 tumor-bearing mice were randomly selected into groups based on mouse weight and tumor size). The mice were purchased from the Shanghai Southern Model Animal Center (SMOC), animal qualification certificate number: 20190002004257. The housing environment was SPF grade.

[0207] Mouse-derived MC38-hSiglec15 cells (Clone #6, cell number ECL-00260) were cultured in DMEM medium containing 10% fetal bovine serum. MC38-hSiglec15 cells in the exponential growth phase were collected for seeding, resuspended in PBS, and cultured at 5 × 10⁶ cells per mouse. 6 Cells were subcutaneously injected at 100 μL into the right scapula of the back. C57BL / 6J-SIGLEC15HuGEMM mice were subcutaneously injected with MC38-hSiglec15 tumor cells to establish an allogeneic colon cancer cell tumor model. The control group served as an hIgG1 isotype control, while the treatment groups consisted of 21F6C6-hH2L4V (10 mg / kg) and 174C11C9-hH2L2 (10 mg / kg), with 8 mice in each group. Both the control and treatment groups received intraperitoneal injections, and efficacy was evaluated based on tumor inhibition rate (TGI).

[0208] 21F6C6-hH2L4V:

[0209] Heavy chain variable region sequence (SEQ ID NO:53):

[0210] EVQLVESGGGLVKPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVA TISSGGSLIYYADSVTG RFTISRDNAKNTLYLQMNSLRAEDTAVYYCVR HGYYYGDSTLYYAMDY WGQGTTVTVSS

[0211] The underlined sequences above are HCDR1, HCDR2 and HCDR3, and their amino acid sequences are shown in SEQ ID NO:1, 3 and 5, respectively.

[0212] Light chain variable region sequence (SEQ ID NO:82):

[0213] DIQMTQSPSSLSASVGDRVTITC RASQSVDYEGDSYMN WYQQKPGKAPKLLIY AASNLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSNEAPLT FGQGTKLEIK

[0214] The underlined sequences above are LCDR1, LCDR2 and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:81, 9 and 10, respectively.

[0215] 174C11C9-hH2L2:

[0216] Heavy chain variable region sequence (SEQ ID NO:69):

[0217] QVQLVQSGAEVKKPGASVKVSCKASGYIFT DYYMN WVRQAPGQGLEWIG VFNPYSGGISYNQKFKG RVTLTVDTSTSTAYMELSSLRSEDTAVYYCAR DYYYLSSHGFYALDY WGQGTTVTVSS

[0218] The underlined sequences above are HCDR1, HCDR2 and HCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:25, 26 and 29, respectively.

[0219] Light chain variable region sequence (SEQ ID NO:70):

[0220] DIQLTQSPSSLSASVGDRVTITC RASESVDSYGNSFIH WYQQKPGKAPKLLMY RASNLES GIPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSNEDPLT FGQGTKLEIK

[0221] The underlined sequences above are LCDR1, LCDR2 and LCDR3, respectively, and their amino acid sequences are shown in SEQ ID NO:30, 32 and 34, respectively.

[0222] Formula for calculating tumor volume: Tumor volume (mm) 3= 1 / 2 × (a × b²) (where a represents the major axis and b represents the minor axis). Data was collected using StudyDirector™ software (version 3.1.399.19, vendor StudylogSystem, Inc., S. San Francisco, CA, USA), including measurements of the tumor's major and minor axes and animal weight. Tumor inhibition rate, TGI (%), was calculated as follows: TGI% = 100 × (1 - ΔT / ΔC). (ΔT and ΔC are the mean tumor volume (MTV) of the treatment group and control group at a specific time point, respectively). t ) - Mean tumor volume at the time of grouping (MTV1)

[0223] All statistical analyses and graphs were performed in the R language environment (version 3.3.1). Unless otherwise specified, all tests were two-tailed tests, and a p-value less than 0.05 was considered statistically significant.

[0224] Experimental results:

[0225] Analysis of the average tumor volume in mice on day 38 after drug administration showed that the average tumor volume in the hIgG1 isotype (10 mg / kg) control group was 1134 mm³ on day 38 after drug administration. 3 In the 21F6C6-hH2L4V (10mg / kg) treatment group, tumors began to disappear on day 6 after administration, and all mice were cured on day 13 after treatment. The tumor volume in all 7 mice remained at 0 mm until day 38. 3 One mouse experienced tumor recurrence, and the overall tumor inhibition rate (TGI) was 107%, which was statistically significant compared to the control group (P < 0.005). In the 174C11C9-hH2L2 (10 mg / kg) treatment group, tumors began to disappear on day 6 after administration, and all mice were cured by day 13. By day 38, the tumor volume in all mice was 0 mm. 3 The tumor inhibition rate (TGI) was 108%, which was statistically significant compared to the control group (P<0.005). Tumor growth in the control and treatment groups is shown in the table below. Figure 7 The weight change curves of the control group and the treatment group over the course of treatment are shown in the figure. Figure 8 The results of this study indicate that, compared with the negative control hIgG1 isotype (10 mg / kg), treatment with 21F6C6-hH2L4V (10 mg / kg) and 174C11C9-hH2L2 (10 mg / kg) alone achieved significant anti-tumor effects in the MC38-hSiglec15 tumor model (P<0.005). Mice were essentially cured, and after prolonged observation following tumor disappearance, there was virtually no tumor recurrence. SEQUENCE LISTING <110> Shanghai Jinmante Biotechnology Co., Ltd. <120> Anti-Siglec-15 antibody and its application in drug preparation <130> <160> 82 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 HCDR1 <400> 1 Ser Tyr Ala Met Ser 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 HCDR2 <400> 2 Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Pro Asp Ser Val Thr 1 5 10 15 Gly <210> 3 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH2 HCDR2 <400> 3 Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Ala Asp Ser Val Thr 1 5 10 15 Gly <210> 4 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH3 / hVH4 HCDR2 <400> 4 Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 5 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 HCDR3 <400> 5 His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met Asp Tyr 1 5 10 15 <210> 6 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 LCDR1 <400> 6 Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn 1 5 10 15 <210> 7 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL1~4 LCDR1 <400> 7 Arg Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn 1 5 10 15 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 LCDR2 <400> 8 Ala Ala Ser Asn Leu Glu Ser 1 5 <210> 9 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL4 LCDR2 <400> 9 Ala Ala Ser Asn Leu Gln Ser 1 5 <210> 10 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 LCDR3 <400> 10 Gln Gln Ser Asn Glu Ala Pro Leu Thr 1 5 <210> 11 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 HCDR1 <400> 11 Asp Tyr Gly Met His 1 5 <210> 12 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 HCDR2 <400> 12 Tyr Ile Ser Ser Gly Ser Ser Ile Ile Asp Tyr Ser Asp Thr Val Lys 1 5 10 15 Gly <210> 13 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 HCDR3 <400> 13 Arg Glu Asp His Tyr Ala Met Asp Tyr 1 5 <210> 14 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 LCDR1 <400> 14 Lys Ala Ser Gln Asp Val Tyr Thr Ala Val Ala 1 5 10 <210> 15 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 LCDR2 <400> 15 Ser Ala Ser Tyr Arg Phe Thr 1 5 <210> 16 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 75E1F2 LCDR3 <400> 16 Gln Gln His Tyr Ser Thr Pro Trp Thr 1 5 <210> 17 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 HCDR1 <400> 17 Asp Tyr Tyr Met His 1 5 <210> 18 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 HCDR2 <400> 18 Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ala Pro Lys Phe Gln 1 5 10 15 Gly <210> 19 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVH4 HCDR2 <400> 19 Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ser Gln Lys Phe Gln 1 5 10 15 Gly <210> 20 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 HCDR3 <400> 20 Gly Trp Leu Gly Tyr Ile Met Asp Phe 1 5 <210> 21 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 LCDR1 <400> 21 Thr Leu Ser Ser Gln His Ser Thr Tyr Thr Ile Asp 1 5 10 <210> 22 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 LCDR2 <400> 22 Leu Lys Glu Asp Gly Ser His Ser Thr Gly Asp 1 5 10 <210> 23 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVL3~4 LCDR2 <400> 23 Leu Lys Glu Asp Gly Ser His Ser Lys Gly Asp 1 5 10 <210> 24 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6 LCDR3 <400> 24 Gly Val Gly Ala Thr Ile Lys Glu Gln Phe Val Tyr Val 1 5 10 <210> 25 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 HCDR1 <400> 25 Asp Tyr Tyr Met Asn 1 5 <210> 26 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 HCDR2 <400> 26 Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 27 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH3 HCDR2 <400> 27 Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Ala Gln Lys Phe Lys 1 5 10 15 Gly <210> 28 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH4 HCDR2 <400> 28 Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 29 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 HCDR3 <400> 29 Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp Tyr 1 5 10 15 <210> 30 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 LCDR1 <400> 30 Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Ile His 1 5 10 15 <210> 31 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVL4 LCDR1 <400> 31 Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Thr Phe Ile His 1 5 10 15 <210> 32 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 LCDR2 <400> 32 Arg Ala Ser Asn Leu Glu Ser 1 5 <210> 33 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVL4 LCDR2 <400> 33 Arg Ala Ser Asn Leu Gln Ser 1 5 <210> 34 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9 LCDR3 <400> 34 Gln Gln Ser Asn Glu Asp Pro Leu Thr 1 5 <210> 35 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 HCDR1 <400> 35 Gly Tyr Asn Met Asn 1 5 <210> 36 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 HCDR2 <400> 36 Tyr Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 37 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 HCDR3 <400> 37 Asp Tyr Gly Ile Asp Tyr 1 5 <210> 38 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 LCDR1 <400> 38 Gln Ala Thr Gln Asp Ile Val Lys Asn Leu Asn 1 5 10 <210> 39 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 LCDR2 <400> 39 Tyr Ala Thr Glu Leu Ala Glu 1 5 <210> 40 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> 255C12B10 LCDR3 <400> 40 Leu Gln Phe Tyr Glu Phe Pro Tyr Thr 1 5 <210> 41 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 heavy chain variable region <400> 41 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ser Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Pro Asp Ser Val 50 55 60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Val Arg His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met 100 105 110 Asp Tyr Trp Gly Pro Gly Thr Ser Val Thr Val Ser Ser 115 120 125 <210> 42 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6 light chain variable region <400> 42 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 43 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain variable region of 75E1F2 <400> 43 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Ile 35 40 45 Thr Tyr Ile Ser Ser Gly Ser Ser Ile Ile Asp Tyr Ser Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asp Thr Leu Phe 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Val Arg Arg Glu Asp His Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 44 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region of 75E1F2 <400> 44 Asp Ile Val Met Thr Gln Ser His Lys Phe Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Tyr Thr Ala 20 25 30 Val Ala Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Phe 35 40 45 Tyr Ser Ala Ser Tyr Arg Phe Thr Gly Val Pro Asp Arg Phe Asn Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Met Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Ser Thr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 45 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain variable region of 124B11F6 <400> 45 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Val Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Lys Gln Arg Thr Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu His Leu Ser Thr Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Gly Trp Leu Gly Tyr Ile Met Asp Phe Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 46 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region of 124B11F6 <400> 46 Gln Leu Val Leu Thr Gln Ser Ser Ser Ala Ser Phe Ser Leu Gly Ala 1 5 10 15 Ser Ala Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 20 25 30 Ile Asp Trp Tyr Gln Gln Gln Pro Leu Lys Pro Pro Lys Tyr Val Met 35 40 45 Glu Leu Lys Glu Asp Gly Ser His Ser Thr Gly Asp Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Ser Ser Gly Ala Asp Arg Tyr Leu Gly Ile Ser 65 70 75 80 Asn Ile Gln Pro Glu Asp Glu Ala Val Tyr Ile Cys Gly Val Gly Ala 85 90 95 Thr Ile Lys Glu Gln Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val 100 105 110 Thr Val Leu 115 <210> 47 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Variable heavy chain region of 174C11C9 <400> 47 Glu Val Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Glu Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 48 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Variable light chain region of 174C11C9 <400> 48 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 20 25 30 Gly Asn Ser Phe Ile His Trp Tyr Gln Gln Arg Pro Gly Arg Pro Pro 35 40 45 Lys Leu Leu Met Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp 65 70 75 80 Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 49 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain variable region of 255C12B10 <400> 49 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Asn Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asn Asn Gly Gly Thr Arg Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ile Asn Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Ile Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr 100 105 110 Val Ser Ser 115 <210> 50 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region of 255C12B10 <400> 50 Glu Ile Gln Met Thr Gln Ser Pro Ser Ser Met Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Ile Thr Ile Thr Cys Gln Ala Thr Gln Asp Ile Val Lys Asn 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Pro Pro Ser Phe Leu Ile 35 40 45 Tyr Tyr Ala Thr Glu Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Ser 65 70 75 80 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Phe Tyr Glu Phe Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 51 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH1 heavy chain variable region <400> 51 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Pro Asp Ser Val 50 55 60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 52 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL1 light chain variable region <400> 52 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Val Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 53 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH2 heavy chain variable region <400> 53 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 54 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL2 light chain variable region <400> 54 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Ala Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Val Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 55 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH3 heavy chain variable region <400> 55 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 56 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL3 light chain variable region <400> 56 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 57 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVH4 heavy chain variable region <400> 57 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Ser Leu Ile Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Gly Tyr Tyr Tyr Gly Asp Ser Thr Leu Tyr Tyr Ala Met 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 58 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hVL4 light chain variable region <400> 58 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 59 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVH1 heavy chain variable region <400> 59 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Val Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Ala Thr Ile Thr Ala Asp Thr Ser Thr Asn Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Gly Trp Leu Gly Tyr Ile Met Asp Phe Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 60 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVL1 light chain variable region <400> 60 Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Phe Ser Leu Gly Ala 1 5 10 15 Ser Ala Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 20 25 30 Ile Asp Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Val Met 35 40 45 Glu Leu Lys Glu Asp Gly Ser His Ser Thr Gly Asp Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser 65 70 75 80 Ser Ile Gln Ser Glu Asp Glu Ala Asp Tyr Ile Cys Gly Val Gly Ala 85 90 95 Thr Ile Lys Glu Gln Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val 100 105 110 Thr Val Leu 115 <210> 61 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVH2 heavy chain variable region <400> 61 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Val Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Gly Trp Leu Gly Tyr Ile Met Asp Phe Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 62 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVL2 light chain variable region <400> 62 Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 20 25 30 Ile Asp Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Val Met 35 40 45 Glu Leu Lys Glu Asp Gly Ser His Ser Thr Gly Asp Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr Ile Cys Gly Val Gly Ala 85 90 95 Thr Ile Lys Glu Gln Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val 100 105 110 Thr Val Leu 115 <210> 63 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVH3 heavy chain variable region <400> 63 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Val Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ala Pro Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Val Arg Gly Trp Leu Gly Tyr Ile Met Asp Phe Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 64 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVL3 light chain variable region <400> 64 Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 20 25 30 Ile Asp Trp Tyr Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Leu Met 35 40 45 Glu Leu Lys Glu Asp Gly Ser His Ser Lys Gly Asp Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr Ile Cys Gly Val Gly Ala 85 90 95 Thr Ile Lys Glu Gln Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val 100 105 110 Thr Val Leu 115 <210> 65 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVH4 heavy chain variable region <400> 65 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Val Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Glu Asp Asp Lys Thr Lys Tyr Ser Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Trp Leu Gly Tyr Ile Met Asp Phe Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser 115 <210> 66 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> 124B11F6-hVL4 light chain variable region <400> 66 Gln Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gln His Ser Thr Tyr Thr 20 25 30 Ile Asp Trp His Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Leu Met 35 40 45 Glu Leu Lys Glu Asp Gly Ser His Ser Lys Gly Asp Gly Ile Pro Asp 50 55 60 Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr Ile Cys Gly Val Gly Ala 85 90 95 Thr Ile Lys Glu Gln Phe Val Tyr Val Phe Gly Gly Gly Thr Lys Val 100 105 110 Thr Val Leu 115 <210> 67 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH1 heavy chain variable region <400> 67 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 68 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVL1 light chain variable region <400> 68 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 20 25 30 Gly Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Met Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Val Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 69 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH2 heavy chain variable region <400> 69 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 70 <211> 111 PRT Artificial Sequence <220> <223> 174C11C9-hVL2 light chain variable region <400> 70 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 20 25 30 Gly Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Met Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 71 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH3 heavy chain variable region <400> 71 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Ala Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 72 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVL3 light chain variable region <400> 72 Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 20 25 30 Gly Asn Ser Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Met Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 73 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVH4 heavy chain variable region <400> 73 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asp Tyr 20 25 30 Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Phe Asn Pro Tyr Ser Gly Gly Ile Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Tyr Tyr Leu Ser Ser His Gly Phe Tyr Ala Leu Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 74 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 174C11C9-hVL4 light chain variable region <400> 74 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr 20 25 30 Gly Asn Thr Phe Ile His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Met Tyr Arg Ala Ser Asn Leu Gln Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Asp Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 75 <211> 263 <212> PRT <213> Artificial Sequence <220> <223> hSiglec-15 extracellular domain <400> 75 Met Glu Lys Ser Ile Trp Leu Leu Ala Cys Leu Ala Trp Val Leu Pro 1 5 10 15 Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu 20 25 30 Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val 35 40 45 Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys 50 55 60 Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile 65 70 75 80 Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala 85 90 95 Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly 100 105 110 Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg 115 120 125 Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val 130 135 140 Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val 145 150 155 160 Arg Leu His Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu 165 170 175 Pro Ser Pro Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu 180 185 190 Pro Pro Pro Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu 195 200 205 Ala Ala Val Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala 210 215 220 Glu Leu Pro Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala 225 230 235 240 Asn Ser Leu Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His 245 250 255 Gly Ala Ser Gly Ala Ser Thr 260 <210> 76 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> hS15-hFc protein <400> 76 Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu Asn Thr Glu 1 5 10 15 Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val Pro Pro Glu 20 25 30 Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys Thr Phe Thr 35 40 45 His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile Trp Arg Ala 50 55 60 Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala Ala Ala Arg 65 70 75 80 Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly Arg Phe Arg 85 90 95 Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg Val Glu Arg 100 105 110 Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val Glu Phe Ala 115 120 125 Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val Arg Leu His 130 135 140 Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu Pro Ser Pro 145 150 155 160 Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu Pro Pro Pro 165 170 175 Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu Ala Ala Val 180 185 190 Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala Glu Leu Pro 195 200 205 Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser Leu 210 215 220 Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala Ser 225 230 235 240 Gly Ala Ser Thr Gly Gly Gly Ser Gly Gly Gly Ser Pro Lys Ser Ser 245 250 255 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 260 265 270 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 275 280 285 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 290 295 300 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 305 310 315 320 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 325 330 335 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 340 345 350 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 355 360 365 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 370 375 380 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 385 390 395 400 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 405 410 415 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 420 425 430 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 435 440 445 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 450 455 460 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 465 470 475 480 Pro Gly Lys <210> 77 <211> 390 <212> PRT <213> Artificial Sequence <220> <223> hS15-D1-hFc <400> 77 Pro Thr Gly Ser Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu 1 5 10 15 Leu Asn Thr Glu Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln 20 25 30 Val Pro Pro Glu Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro 35 40 45 Cys Thr Phe Thr His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala 50 55 60 Ile Trp Arg Ala Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys 65 70 75 80 Ala Ala Ala Arg Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His 85 90 95 Gly Arg Phe Arg Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu 100 105 110 Arg Val Glu Arg Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg 115 120 125 Val Glu Phe Ala Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly 130 135 140 Val Arg Leu His Val Thr Ala Ala Asp Ile Glu Gly Arg Met Asp Pro 145 150 155 160 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 165 170 175 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 180 185 190 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 195 200 205 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 210 215 220 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 225 230 235 240 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 245 250 255 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 260 265 270 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 275 280 285 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 290 295 300 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 305 310 315 320 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 325 330 335 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 340 345 350 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 355 360 365 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 370 375 380 Ser Leu Ser Pro Gly Lys 385 390 <210> 78 <211> 262 <212> PRT <213> Artificial Sequence <220> <223> hS15-His protein <400> 78 Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu Asn Thr Glu 1 5 10 15 Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val Pro Pro Glu 20 25 30 Val Ser Ala Glu Ala Gly Asp Ala Ala Val Leu Pro Cys Thr Phe Thr 35 40 45 His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile Trp Arg Ala 50 55 60 Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala Ala Ala Arg 65 70 75 80 Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly Arg Phe Arg 85 90 95 Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg Val Glu Arg 100 105 110 Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val Glu Phe Ala 115 120 125 Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val Arg Leu His 130 135 140 Val Thr Ala Ala Pro Arg Ile Val Asn Ile Ser Val Leu Pro Ser Pro 145 150 155 160 Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu Pro Pro Pro 165 170 175 Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Ser Leu Ala Ala Val 180 185 190 Arg Ser Pro Arg Glu Gly His Gly His Leu Val Thr Ala Glu Leu Pro 195 200 205 Ala Leu Thr His Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser Leu 210 215 220 Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala Ser 225 230 235 240 Gly Ala Ser Thr Gly Gly Gly Ser Gly Gly Gly Ser His His His His 245 250 255 His His His His His His 260 <210> 79 <211> 262 <212> PRT <213> Artificial Sequence <220> <223> Cynomolgus monkey S15-His protein <400> 79 Phe Val Arg Thr Lys Ile Asp Thr Thr Glu Asn Leu Leu Asn Thr Glu 1 5 10 15 Val His Ser Ser Pro Ala Gln Arg Trp Ser Met Gln Val Pro Ala Glu 20 25 30 Val Ser Ala Ala Ala Gly Asp Ala Ala Val Leu Pro Cys Thr Phe Thr 35 40 45 His Pro His Arg His Tyr Asp Gly Pro Leu Thr Ala Ile Trp Arg Ala 50 55 60 Gly Glu Pro Tyr Ala Gly Pro Gln Val Phe Arg Cys Ala Ala Ala Arg 65 70 75 80 Gly Ser Glu Leu Cys Gln Thr Ala Leu Ser Leu His Gly Arg Phe Arg 85 90 95 Leu Leu Gly Asn Pro Arg Arg Asn Asp Leu Ser Leu Arg Val Glu Arg 100 105 110 Leu Ala Leu Ala Asp Asp Arg Arg Tyr Phe Cys Arg Val Glu Phe Ala 115 120 125 Gly Asp Val His Asp Arg Tyr Glu Ser Arg His Gly Val Arg Leu His 130 135 140 Val Thr Ala Ala Pro Arg Ile Ile Asn Ile Ser Val Leu Pro Gly Pro 145 150 155 160 Ala His Ala Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu Pro Pro Pro 165 170 175 Ala Leu Ala Trp Ser Gly Pro Ala Leu Gly Asn Gly Ser Ala Ala Val 180 185 190 Pro Ser Ser Gly Gln Gly His Gly His Leu Val Thr Ala Glu Leu Pro 195 200 205 Ala Leu Asn His Asp Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser Leu 210 215 220 Gly Arg Ser Glu Ala Ser Val Tyr Leu Phe Arg Phe His Gly Ala Ser 225 230 235 240 Gly Ala Ser Thr Gly Gly Gly Ser Gly Gly Gly Ser His His His His 245 250 255 His His His His His His 260 <210> 80 <211> 257 <212> PRT <213> Artificial Sequence <220> <223> Mouse S15-His protein <400> 80 Arg Arg Asp Ala Ser Gly Asp Leu Leu Asn Thr Glu Ala His Ser Ala 1 5 10 15 Pro Ala Gln Arg Trp Ser Met Gln Val Pro Ala Glu Val Asn Ala Glu 20 25 30 Ala Gly Asp Ala Ala Val Leu Pro Cys Thr Phe Thr His Pro His Arg 35 40 45 His Tyr Asp Gly Pro Leu Thr Ala Ile Trp Arg Ser Gly Glu Pro Tyr 50 55 60 Ala Gly Pro Gln Val Phe Arg Cys Thr Ala Ala Pro Gly Ser Glu Leu 65 70 75 80 Cys Gln Thr Ala Leu Ser Leu His Gly Arg Phe Arg Leu Leu Gly Asn 85 90 95 Pro Arg Arg Asn Asp Leu Ser Leu Arg Val Glu Arg Leu Ala Leu Ala 100 105 110 Asp Ser Gly Arg Tyr Phe Cys Arg Val Glu Phe Thr Gly Asp Ala His 115 120 125 Asp Arg Tyr Glu Ser Arg His Gly Val Arg Leu Arg Val Thr Ala Ala 130 135 140 Ala Pro Arg Ile Val Asn Ile Ser Val Leu Pro Gly Pro Ala His Ala 145 150 155 160 Phe Arg Ala Leu Cys Thr Ala Glu Gly Glu Pro Pro Pro Ala Leu Ala 165 170 175 Trp Ser Gly Pro Ala Pro Gly Asn Ser Ser Ala Ala Leu Gln Gly Gln 180 185 190 Gly His Gly Tyr Gln Val Thr Ala Glu Leu Pro Ala Leu Thr Arg Asp 195 200 205 Gly Arg Tyr Thr Cys Thr Ala Ala Asn Ser Leu Gly Arg Ala Glu Ala 210 215 220 Ser Val Tyr Leu Phe Arg Phe His Gly Ala Pro Gly Thr Ser Thr Gly 225 230 235 240 Gly Gly Ser Gly Gly Gly Ser His His His His His His His His His 245 250 255 His <210> 81 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hH2L4V LCDR1 <400> 81 Arg Ala Ser Gln Ser Val Asp Tyr Glu Gly Asp Ser Tyr Met Asn 1 5 10 15 <210> 82 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> 21F6C6-hH2L4V light chain variable region sequence <400> 82 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Asp Tyr Glu 20 25 30 Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Asn 85 90 95 Glu Ala Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110

Claims

1. An isolated antibody or antigen-binding fragment thereof that binds Siglec-15, characterized in that, The isolated antibody or its antigen-binding fragment that binds to Siglec-15 includes a heavy chain variable region and a light chain variable region. The heavy chain variable region includes HCDR1, HCDR2, and HCDR3, and the light chain variable region includes LCDR1, LCDR2, and LCDR3. The heavy chain variable region HCDR1 sequence is shown in SEQ ID NO:1, the HCDR2 sequence is shown in SEQ ID NO:3, and the HCDR3 sequence is shown in SEQ ID NO:

5. The light chain variable region LCDR1 sequence is shown in SEQ ID NO:81, the LCDR2 sequence is shown in SEQ ID NO:9, and the LCDR3 sequence is shown in SEQ ID NO:

10.

2. The isolated antibody or antigen-binding fragment of Siglec-15 according to claim 1, characterized in that, The isolated antibody or its antigen-binding fragment that binds to Siglec-15 is a murine antibody, a chimeric antibody, a humanized antibody, or its antigen-binding fragment.

3. The isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 according to claim 2, characterized in that, The isolated antibody or its antigen-binding fragment that binds to Siglec-15 is a humanized antibody or its antigen-binding fragment.

4. The isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 according to claim 1, characterized in that, The heavy chain variable region is as shown in SEQ ID NO:53, and / or the light chain variable region is as shown in SEQ ID NO:

82.

5. The isolated antibody or antigen-binding fragment thereof binding to Siglec-15 according to any one of claims 1-4, characterized in that, The antibody also includes a constant region.

6. The isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 according to claim 5, characterized in that, The constant region includes the IgG1 or IgG4 constant region.

7. A nucleic acid encoding the isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 as described in any one of claims 1-6.

8. An expression vector comprising the nucleic acid of claim 7.

9. A host cell comprising the expression vector of claim 8.

10. A method for preparing the isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 according to any one of claims 1-6, the method comprising: (a) Culture host cells containing nucleic acids encoding the antibody or its antigen-binding fragment in a culture medium under conditions that enable nucleic acid expression, thereby producing a polypeptide comprising a light chain variable region and a heavy chain variable region; and (b) Recover the polypeptide from the host cell or culture medium.

11. A composition comprising, in combination with a pharmaceutically acceptable carrier or diluent, the isolated antibody or antigen-binding fragment thereof binding to Siglec-15 as described in any one of claims 1-6.

12. The use of the isolated antibody or antigen-binding fragment thereof that binds to Siglec-15 according to any one of claims 1-6, or the composition according to claim 11, in the preparation of a medicament for treating Siglec-15-related diseases, wherein the Siglec-15-related diseases are selected from melanoma, glioblastoma, ovarian cancer, lung cancer, and colon cancer.

Citation Information

Patent Citations

  • Antibodies for siglec-15 and methods of use thereof

    CN110035769A